Workflow
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
Neo-Concept International Group Holdings LimitedNeo-Concept International Group Holdings Limited(US:NCI) GlobeNewswire News Room·2025-08-25 11:30

Core Insights - BriaCell Therapeutics Corp. has received a non-dilutive research grant of $2,054,651 from the National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer [1][7] - The grant will support the completion of manufacturing for Bria-PROS+ and fund a Phase 1/2a clinical trial in patients with advanced prostate cancer [2][7] - The Bria-OTS+ platform aims to simplify and reduce the costs associated with traditional personalized cancer treatments, addressing an urgent unmet medical need in cancer care [4][7] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [4] - The company is advancing its personalized off-the-shelf immunotherapy approach, which is expected to significantly improve personalized cancer treatment [4][7] Clinical Study Insights - Dr. William Oh, the Principal Investigator for the upcoming clinical study, emphasized the need for effective treatments for metastatic hormone-sensitive prostate cancer, highlighting the urgency of the medical need [3] - The Phase 1/2a clinical trial will investigate the efficacy of Bria-PROS+ in patients suffering from advanced prostate cancer [2][3]